SCHEMBL22322792

SCHEMBL22322792

CCOC(=O)c1cc(Cc2ccc(Cl)cc2)c2cccn2n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM1 P11229 9/20 0.48
MAPT P10636 3/20 0.46
LMNA P02545 2/20 0.46
NPC1 O15118 1/20 0.46
TP53 P04637 1/20 0.46
RAB9A P51151 1/20 0.46
PDE3B Q13370 1/20 0.44
PDE3A Q14432 1/20 0.44
SPR P35270 1/20 0.44
KDM4E B2RXH2 3/20 0.43
NPSR1 Q6W5P4 2/20 0.43
MAPK1 P28482 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
ELANE P08246 1/20 0.43
ALDH1A1 P00352 2/20 0.43
HPGD P15428 2/20 0.43
TNF P01375 1/20 0.43
HSP90AA1 P07900 1/20 0.43
ALOX12 P18054 1/20 0.43
CCR6 P51684 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21858992 0.89 CHRM1 (0.53) CHRM1PDE3BPDE3ASPRELANE
SCHEMBL21938332 0.85 CHRM1 (0.61) CHRM1SPR
SCHEMBL21858982 0.85 CHRM1 (0.51) CHRM1KDM4E
SCHEMBL30436149 0.82 CHRM1 (0.49) CHRM1NPC1RAB9AKDM4EALDH1A1
SCHEMBL25348205 0.82 SPR (0.49) MAPTNPC1TP53RAB9ASPR
SCHEMBL21859079 0.82 CHRM1 (0.64) CHRM1SPR
SCHEMBL21938331 0.78 CHRM1 (0.40) CHRM1MAPTTP53SPR
SCHEMBL25348758 0.78 SPR (0.44) MAPTLMNANPC1TP53RAB9A
SCHEMBL21938249 0.78 CHRM1 (0.77) CHRM1MAPTNPC1RAB9AKDM4E
SCHEMBL30540553 0.76 SPR (0.48) MAPTLMNATP53SPRKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12122779-B2 Pyrrolo-pyridazine derivatives as muscarinic M1 receptor positive allosteric modulators SUVEN LIFE SCIENCES LIMITED (IN) 2024-10-22 US disclosed
CN-113166160-B Pyrrolopyridazine derivatives as modulators of the positive allosteric of the muscarinic M1 receptor 苏文生命科学有限公司 2023-12-19 CN disclosed
EP-3867254-B1 PYRROLO-PYRIDAZINE DERIVATIVES AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS SUVEN LIFE SCIENCES LTD (IN) 2023-05-31 EP disclosed
US-20210340148-A1 PYRROLO-PYRIDAZINE DERIVATIVES AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS SUVEN LIFE SCIENCES LIMITED (IN) 2021-11-04 US disclosed
US-20210340148-A1 PYRROLO-PYRIDAZINE DERIVATIVES AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS SUVEN LIFE SCIENCES LIMITED (IN) 2021-11-04 US disclosed
WO-2020079606-A9 PYRROLO-PYRIDAZINE DERIVATIVES AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS SUVEN LIFE SCIENCES LIMITED (IN) 2020-08-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210340148-A1 PYRROLO-PYRIDAZINE DERIVATIVES AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS CHRM1, CHRM5, CHRM2 CHRM1 1/4885MAPT 193/4885LMNA 4015/4885
US-12122779-B2 Pyrrolo-pyridazine derivatives as muscarinic M1 receptor positive allosteric modulators CHRM1, CHRM5, CHRM2 CHRM1 1/4885MAPT 193/4885LMNA 4015/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.